Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#3567 Metastatic mixed VIPoma/PPoma-induced diarrhoea causing renal failure

Introduction: Pancreatic neuroendocrine tumors (pNETs) are rare, but despite better prognosis than other pancreatic tumors, their presentation is often occult. VIPomas are a further subtype secreting vasoactive intestinal peptide (VIP). Associated symptoms are particularly non-specific, with watery diarrhoea and electrolyte disturbance which mimics less sinister pathology. Consequently, this presentation is often overlooked resulting in tumor progression and delayed diagnosis, hindering effective management.

Conference:

Presenting Author: Monaghan A

Authors: Monaghan A, Brown G, Takhar A,

Keywords: Pancreatic Neuroendocrine Tumor, Neuroendocrine Tumor, pNET, Vasoactive Intestinal Peptide, VIPoma, Pancreatic Polypeptide,

#1857 Association between Neuroendocrine Tumors (NETs) Biomarkers and Tumor Burden Based on Total 68Ga-DOTATATE-Avid Tumor Volume (TV) Measurements

Introduction: No study has yet assessed the utility of biochemical biomarkers for evaluating NET burden using 68Ga-DOTATATE PET/CT.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Tirosh A, Papadakis G, Millo C, Sadowski S, Herscovitch P,

Keywords: PET burden,

#1853 24 Hour Urinary 5-Hydroxyindoleacetic Acid (5HIAA) and Vasoactive Intestinal Peptide (VIP) Doubling-Times (DTs) Predict Disease-Specific Mortality (DSM) in Patients with Neuroendocrine Tumors (NETs)

Introduction: New clinical prognostic tools are needed in order to select patients with NETs that are at higher risk of DSM. Biochemical biomarker DT is used clinically for prognosis prediction in several solid malignancies

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Tirosh A

Authors: Tirosh A, Nilubol N, Patel D, Kebebew E,

Keywords: doubling time, biomarker, prognosis,

#1261 Emergency Therapy for Liver Metastases from Advanced VIPoma: Surgery or Transarterial Chemoembolization

Introduction: VIPoma is a rare neuroendocrine tumor (NET) with a high potential to develop hepatic metastases and poor prognosis. The primitive tumor is non-symptomatic and usually localized within the pancreas. Liver metastasis drove the prognosis and induced profuse watery diarrhea or renal failure.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Coriat R

Authors: Dréanic J, Lepère C, Mostafa E, Gouya H, Rougier P,

Keywords: vipoma, hepatectomy, Trans Arterial Chemo Embolization (TACE), neuroendocrine tumors (NET), vasoactive intestinal peptide (VIP), systemic chemotherapy,

#493 Pasireotide and Octreotide LAR Was an Effective Combination in a Patient with Small Intestinal NET with Hypokalemia and a High Level of VIP

Introduction: Small Intestinal neuroendocrine tumors (NET) are argentaffin-positive tumors that progress slowly.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Kozlovacki G, Welin S, Eriksson B, Granberg D, Gaasvik-Blomqvist L,

Keywords: pasireotide, octreotide LAR, small intestinal NET, diarrhea, VIP ,